Marked Enhancement of the Antigen-Specific Immune Response by Combining Plasmid DNA-Based Immunization with a Schiff Base-Forming Drug-Reference-Cited by-同舟云学术

Marked Enhancement of the Antigen-Specific Immune Response by Combining Plasmid DNA-Based Immunization with a Schiff Base-Forming Drug

Published:2002-12 Issue:12 Volume:70 Page:6652-6657
ISSN:0019-9567
Container-title:Infection and Immunity
language:en
Short-container-title:Infect Immun

Author:

Charo Jehad¹²,Sundbäck Maria¹,Wasserman Ken³,Ciupitu Anne-Marie T.¹,Mirzai Babak²,van der Zee Ruurd⁴,Kiessling Rolf¹²

Affiliation:

1. Cancer Center Karolinska (CCK), Karolinska Hospital, S-17176

2. Microbiology and Tumor Biology Center (MTC), Karolinska Institute, S-17177, Stockholm, Sweden

3. American Type Culture Collection, Manassas, Virginia 20110

4. Department of Immunology, Faculty of Veterinary Medicine, Utrecht University, 3508 TD Utrecht, The Netherlands

Abstract

ABSTRACT Although plasmid DNA (pDNA)-based immunization has proven efficacy, the level of immune responses that is achieved by this route of vaccination is often lower than that induced by traditional vaccines, especially for primates and humans. We report here a simple and potent method to enhance pDNA-based vaccination by using two different plasmids encoding viral or bacterial antigens. This method is based on coadministration of low concentrations of a recently described immunopotentiating, Schiff base-forming drug called tucaresol which has led to significant augmentation of antigen-specific humoral and cellular immune responses. Our data suggest that enhancement of the immune response with tucaresol might provide a powerful tool for the further development of pDNA-based immunization for humans.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Immunology,Microbiology,Parasitology

Link

https://journals.asm.org/doi/pdf/10.1128/IAI.70.12.6652-6657.2002

Reference44 articles.

1. Bednarek, M. A., S. Y. Sauma, M. C. Gammon, G. Porter, S. Tamhankar, A. R. Williamson, and H. J. Zweerink. 1991. The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA-A2. J. Immunol.147:4047-4053.

2. Bloom, B. R., and J. D. McKinney. 1999. The death and resurrection of tuberculosis. Nat. Med.5:872-874.

3. Charo, J., A. M. Ciupitu, A. Le Chevalier De Preville, P. Trivedi, G. Klein, J. Hinkula, and R. Kiessling. 1999. A long-term memory obtained by genetic immunization results in full protection from a mammary adenocarcinoma expressing an EBV gene. J. Immunol.163:5913-5919.

4. Charo, J., A. Geluk, M. Sundbäck, B. Mirzai, A. D. Diehl, K. J. Malmberg, A. Achour, S. Huriguchi, K. E. van Meijgaarden, J. W. Drijfhout, N. Beekman, P. van Veelen, F. Ossendorp, T. Ottenhoff, and R. Kiessling. 2001. Identification of a common pathogen-specific HLA class I A∗0201 restricted cytotoxic T-cell epitope encoded within the heat shock protein 65. Eur. J. Immunol.31:3602-3611.

5. Charo, J., M. Sundbäck, A. Geluk, T. Ottenhoff, and R. Kiessling. 2001. DNA immunization of HLA transgenic mice with a plasmid expressing the mycobacterial heat shock protein 65 results in HLA class I- and II-restricted T-cell responses that can be augmented by cytokines. Hum. Gene Ther.12:1797-1804.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis of immunostimulatory saponins: A sweet challenge for carbohydrate chemists;Carbohydrate Research;2023-08

2. Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresol;Bioorganic & Medicinal Chemistry;2014-11

3. Lipid tucaresol as an adjuvant for methamphetamine vaccine development;Chem. Commun.;2014

4. Analysis of theenvV3 Sequences Obtained from Patients with HIV Type 1 Infection Treated with the Immune Modulant Agent Tucaresol;AIDS Research and Human Retroviruses;2005-09

5. Protective immunogenicity of the paraflagellar rod protein 2 of Leishmania mexicana;Vaccine;2005-01